Patents by Inventor Tomoko Date

Tomoko Date has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acid construct comprising nucleic acid derived from genome of hepatitis C virus of genotype 1B, hepatitis C virus genome-replicating cells transfected with the same, and method for producing infectious hepatitis C virus particles
    Patent number: 9234184
    Abstract: A subgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and a fullgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and infectious HCV particle-producing ability, each derived from a novel HCV of genotype 1b, are provided. Particularly, a subgenomic replicon RNA (nucleic acid) and a fullgenomic replicon RNA (nucleic acid), each derived from an HCV genome of the NC1 strain which is a novel HCV genotype 1b isolated from a patient with acute severe hepatitis C, are provided.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: January 12, 2016
    Assignees: Japan as Represented by Director-General of National Institute of Infectious Diseases, Public University Corporation Nagoya City University, Toray Industries, Inc.
    Inventors: Takaji Wakita, Tomoko Date, Yasuhito Tanaka, Masashi Mizokami
  • Modified human hepatitis C virus genomic RNA that can be autonomously replicated
    Patent number: 9175269
    Abstract: The present invention provides modified hepatitis C virus genomic RNA, comprising nucleotide sequences of genomic RNA portions of two or more types of hepatitis C viruses, which comprises a 5? untranslated region, a core protein coding sequence, an E1 protein coding sequence, a p7 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3? untranslated region, and which can be autonomously replicated. In particular, the present invention relates to modified hepatitis C virus genomic RNA, which can be autonomously replicated by substitution of the RNA sequence portion encoding NS3, NS4, NS5A, and NS5B proteins of hepatitis C virus genomic RNA with a partial RNA sequence encoding NS3, NS4, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO: 1.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: November 3, 2015
    Assignees: TORAY INDUSTRIES, INC., TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Ralf Bartenschlager, Jun-ichi Tanabe, Saburo Sone
  • NUCLEIC ACID CONSTRUCT COMPRISING NUCLEIC ACID DERIVED FROM GENOME OF HEPATITIS C VIRUS OF GENOTYPE 1B, HEPATITIS C VIRUS GENOME-REPLICATING CELLS TRANSFECTED WITH THE SAME, AND METHOD FOR PRODUCING INFECTIOUS HEPATITIS C VIRUS PARTICLES
    Publication number: 20140302082
    Abstract: A subgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and a fullgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and infectious HCV particle-producing ability, each derived from a novel HCV of genotype 1b, are provided. Particularly, a subgenomic replicon RNA (nucleic acid) and a fullgenomic replicon RNA (nucleic acid), each derived from an HCV genome of the NC1 strain which is a novel HCV genotype 1b isolated from a patient with acute severe hepatitis C, are provided.
    Type: Application
    Filed: March 30, 2012
    Publication date: October 9, 2014
    Applicants: JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASE, PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, TORAY INDUSTRIES, INC.
    Inventors: Takaji Wakita, Tomoko Date, Yasuhito Tanaka, Masashi Mizokami
  • Nucleic acid derived from hepatitis C virus and expression vector, transformed cell, and hepatitis C virus particles each prepared by using the same
    Patent number: 8834893
    Abstract: The present invention provides a nucleic acid comprises a 5? untranslated region, an NS3 protein coding region, an NS4A protein coding region, an NS4B protein coding region, an NS5A protein coding region, an NS5B protein coding region, and a 3? untranslated region of a hepatitis C virus genome, wherein the nucleic acid has nucleotide substitutions causing one or more amino acid substitutions selected from the group consisting of M(1205)K, F(1548)L, C(1615)W, T(1652)N, A(2196)T, A(2218)S, H(2223)Q, Q(2281)R, K(2520)N, and G(2374)S, as defined using the amino acid sequence shown in SEQ ID NO: 6 in the Sequence Listing as a reference sequence, in the NS3 protein coding region, the NS5A protein coding region, or the NS5B protein coding region.
    Type: Grant
    Filed: December 25, 2009
    Date of Patent: September 16, 2014
    Assignees: Toray Industries, Inc., Japan as Represented by Director-General of National Institute of Infectious Diseases, Tokyo Metropolitan Institute of Medical Science
    Inventors: Takaji Wakita, Tomoko Date, Hitoshi Takahashi
  • Nucleic acid construct containing a nucleic acid derived from the genome of hepatitis C virus (HCV) of genotype 2a, and a cell having such nucleic acid construct introduced therein
    Patent number: 8754061
    Abstract: The present invention relates to a replicon RNA comprising a nucleotide sequence at least containing the 5? untranslated region, the nucleotide sequence encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein, and the 3? untranslated region on the genomic RNA of hepatitis C virus of genotype 2a.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: June 17, 2014
    Assignees: Toray Industries, Inc., Tokyo Metropolitan Institute of Medical Science
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date
  • Nucleic acid construct containing full length genome of human hepatitis C virus, recombinant full length virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis C virus particle
    Patent number: 8460912
    Abstract: The present invention provides a method for replicating efficiently an RNA containing fulllength HCV genomic sequence and a method for producing HCV virus particles containing fulllength HCV replicon RNA or fulllength HCV genomic RNA by using a cell culture system. Further, the present invention relates to a method for producing hepatitis C virus particles which comprises culturing a cell, into which a replicon RNA comprising a nucleotide sequence comprising a fulllength genomic RNA sequence of hepatitis C virus of the genotype 2a, at least one selectable marker gene and/or at least one reporter gene and at least one IRES sequence or the fulllength genomic RNA of hepatitis C virus of the genotype 2a is introduced, and generating virus particles in the culture medium. Still further the present invention relates also to a hepatitis C vaccine and an antibody against hepatitis C virus particles.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: June 11, 2013
    Assignees: Tokyo Metropolitan Institute of Medical Science, Toray Industries, Inc.
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Jun-ichi Tanabe, Saburo Sone
  • Modified human hepatitis C virus genomic RNA that can be autonomously replicated
    Patent number: 8454973
    Abstract: The present invention provides modified hepatitis C virus genomic RNA, comprising nucleotide sequences of genomic RNA portions of two or more types of hepatitis C viruses, which comprises a 5? untranslated region, a core protein coding sequence, an E1 protein coding sequence, a p7 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3? untranslated region, and which can be autonomously replicated. In particular, the present invention relates to modified hepatitis C virus genomic RNA, which can be autonomously replicated by substitution of the RNA sequence portion encoding NS3, NS4, NS5A, and NS5B proteins of hepatitis C virus genomic RNA with a partial RNA sequence encoding NS3, NS4, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO: 1.
    Type: Grant
    Filed: August 24, 2005
    Date of Patent: June 4, 2013
    Assignees: Tokyo Metropolitan Institute of Medical Science, Toray Industries, Inc.
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Ralf Bartenschlager, Jun-ichi Tanabe, Saburo Sone
  • Nucleic acid construct containing a nucleic acid derived from the genome of hepatitis C virus (HCV) of genotype 2a, and a cell having such nucleic acid construct introduced therein
    Patent number: 8383371
    Abstract: The present invention relates to a replicon RNA comprising a nucleotide sequence at least containing the 5? untranslated region, the nucleotide sequence encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein, and the 3? untranslated region on the genomic RNA of hepatitis C virus of genotype 2a.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: February 26, 2013
    Assignees: Toray Industries, Inc., Tokyo Metropolitan Institute of Medical Science
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date
  • NUCLEIC ACID DERIVED FROM HEPATITIS C VIRUS AND EXPRESSION VECTOR, TRANSFORMED CELL, AND HEPATITIS C VIRUS PARTICLES EACH PREPARED BY USING THE SAME
    Publication number: 20120003720
    Abstract: The present invention provides a nucleic acid comprises a 5? untranslated region, an NS3 protein coding region, an NS4A protein coding region, an NS4B protein coding region, an NS5A protein coding region, an NS5B protein coding region, and a 3? untranslated region of a hepatitis C virus genome, wherein the nucleic acid has nucleotide substitutions causing one or more amino acid substitutions selected from the group consisting of M(1205)K, F(1548)L, C(1615)W, T(1652)N, A(2196)T, A(2218)S, H(2223)Q, Q(2281)R, K(2520)N, and G(2374)S, as defined using the amino acid sequence shown in SEQ ID NO: 6 in the Sequence Listing as a reference sequence, in the NS3 protein coding region, the NS5A protein coding region, or the NS5B protein coding region.
    Type: Application
    Filed: December 25, 2009
    Publication date: January 5, 2012
    Inventors: Takaji Wakita, Tomoko Date, Hitoshi Takahashi
  • Nucleic acid and gene derived from novel HCV strain and replicon-replicating cell using said gene
    Patent number: 8022197
    Abstract: The present invention relates to a gene derived from a novel fulminant hepatitis C virus strain, an HCV replicon RNA with a high replication efficiency obtained using the gene, and an HCV replicon-replicating cell transfected with the replicon RNA. When the HCV replicon RNA and the HCV replicon-replicating cell of the present invention are used, HCV proteins can be continuously produced in a large amount.
    Type: Grant
    Filed: September 16, 2004
    Date of Patent: September 20, 2011
    Assignees: Tokyo Metropolitan Organization for Medical Research, Toray Industries Inc.
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto
  • Nucleic acid construct containing a nucleic acid derived from the genome of hepatitis C virus (HCV) of genotype 2A, and a cell having such nucleic acid construct introduced therein
    Patent number: 7935676
    Abstract: The present invention relates to a replicon RNA comprising a nucleotide sequence at least containing the 5? untranslated region, the nucleotide sequence encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein, and the 3? untranslated region on the genomic RNA of hepatitis C virus of genotype 2a.
    Type: Grant
    Filed: November 25, 2003
    Date of Patent: May 3, 2011
    Assignees: Toray Industries Inc., Tokyo Metropolitan Organization for Medical Research, Ralf Bartenschlager
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date
  • NUCLEIC ACID CONSTRUCT CONTAINING A NUCLEIC ACID DERIVED FROM THE GENOME OF HEPATITIS C VIRUS (HCV) OF GENOTYPE 2a, AND A CELL HAVING SUCH NUCLEIC ACID CONSTRUCT INTRODUCED THEREIN
    Publication number: 20110092688
    Abstract: The present invention relates to a replicon RNA comprising a nucleotide sequence at least containing the 5? untranslated region, the nucleotide sequence encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein, and the 3? untranslated region on the genomic RNA of hepatitis C virus of genotype 2a.
    Type: Application
    Filed: December 1, 2010
    Publication date: April 21, 2011
    Applicants: TORAY INDUSTRIES, INC., Tokyo Metropolitan Organization for Medical Research
    Inventors: Takaji WAKITA, Takanobu Kato, Tomoko Date
  • Nucleic acid and gene derived from novel HCV strain and replicon-replicating cell using said gene
    Patent number: 7790448
    Abstract: The present invention relates to a gene derived from a novel fulminant hepatitis C virus strain, an HCV replicon RNA with a high replication efficiency obtained using the gene, and an HCV replicon-replicating cell transfected with the replicon RNA. When the HCV replicon RNA and the HCV replicon-replicating cell of the present invention are used, HCV proteins can be continuously produced in a large amount.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: September 7, 2010
    Assignees: Tokyo Metropolitan Organization for Medical Research, Toray Industries, Inc.
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto
  • Nucleic acid construct containing full length genome of human hepatitis C virus, recombinant full length virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis C virus particle
    Publication number: 20100047896
    Abstract: The present invention provides a method for replicating efficiently an RNA containing fulllength HCV genomic sequence and a method for producing HCV virus particles containing fulllength HCV replicon RNA or fulllength HCV genomic RNA by using a cell culture system. Further, the present invention relates to a method for producing hepatitis C virus particles which comprises culturing a cell, into which a replicon RNA comprising a nucleotide sequence comprising a fulllength genomic RNA sequence of hepatitis C virus of the genotype 2a, at least one selectable marker gene and/or at least one reporter gene and at least one IRES sequence or the fulllength genomic RNA of hepatitis C virus of the genotype 2a is introduced, and generating virus particles in the culture medium. Still further the present invention relates also to a hepatitis C vaccine and an antibody against hepatitis C virus particles.
    Type: Application
    Filed: August 21, 2009
    Publication date: February 25, 2010
    Applicants: Tokyo Metropolitan Organization for Medical Research, TORAY INDUSTRIES, INC.
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Jun-ichi Tanabe, Saburo Sone
  • Nucleic acid construct containing fulllength genome of human hepatitis C virus, recombinant fulllength virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis C virus Particle
    Patent number: 7659103
    Abstract: The present invention provides a method for replicating efficiently an RNA containing fulllength HCV genomic sequence and a method for producing HCV virus particles containing fulllength HCV replicon RNA or fulllength HCV genomic RNA by using a cell culture system. Further, the present invention relates to a method for producing hepatitis C virus particles which comprises culturing a cell, into which a replicon RNA comprising a nucleotide sequence comprising a fulllength genomic RNA sequence of hepatitis C virus of the genotype 2a, at least one selectable marker gene and/or at least one reporter gene and at least one IRES sequence or the fulllength genomic RNA of hepatitis C virus of the genotype 2a is introduced, and generating virus particles in the culture medium. Still further the present invention relates also to a hepatitis C vaccine and an antibody against hepatitis C virus particles.
    Type: Grant
    Filed: February 21, 2005
    Date of Patent: February 9, 2010
    Assignees: Tokyo Metropolitan Organization For Medical Research, Toray Industries, Inc.
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Jun-ichi Tanabe, Saburo Sone
  • Modified Human Hepatitis C Virus Genomic RNA That can be Autonomously Replicated
    Publication number: 20090176200
    Abstract: The present invention provides modified hepatitis C virus genomic RNA, comprising nucleotide sequences of genomic RNA portions of two or more types of hepatitis C viruses, which comprises a 5? untranslated region, a core protein coding sequence, an E1 protein coding sequence, a p7 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3? untranslated region, and which can be autonomously replicated. In particular, the present invention relates to modified hepatitis C virus genomic RNA, which can be autonomously replicated by substitution of the RNA sequence portion encoding NS3, NS4, NS5A, and NS5B proteins of hepatitis C virus genomic RNA with a partial RNA sequence encoding NS3, NS4, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO: 1.
    Type: Application
    Filed: August 24, 2005
    Publication date: July 9, 2009
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Ralf Bartenschlager, Jun-ichi Tanabe, Saburo Sone
  • Nucleic acid and gene derived from novel HCV strain and replicon-replicating cell using said gene
    Publication number: 20090042181
    Abstract: The present invention relates to a gene derived from a novel fulminant hepatitis C virus strain, an HCV replicon RNA with a high replication efficiency obtained using the gene, and an HCV replicon-replicating cell transfected with the replicon RNA. When the HCV replicon RNA and the HCV replicon-replicating cell of the present invention are used, HCV proteins can be continuously produced in a large amount.
    Type: Application
    Filed: September 12, 2007
    Publication date: February 12, 2009
    Applicants: Tokyo Metropolitan Organization for Medical Research, TORAY INDUSTRIES, INC.
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto
  • Nucleic Acid and Gene Derived from Novel HCV Strain and Replicon-Replicating Cell Using Said Gene
    Publication number: 20090035747
    Abstract: The present invention relates to a gene derived from a novel fulminant hepatitis C virus strain, an HCV replicon RNA with a high replication efficiency obtained using the gene, and an HCV replicon-replicating cell transfected with the replicon RNA. When the HCV replicon RNA and the HCV replicon-replicating cell of the present invention are used, HCV proteins can be continuously produced in a large amount.
    Type: Application
    Filed: September 16, 2004
    Publication date: February 5, 2009
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto
  • Nucleic Acid Construct Containing Fulllength Genome of Human Hepatitis C Virus, Recombinant Fulllength Virus Genome-Replicating Cells Having the Nucleic Acid Construct Transferred Thereinto and Method of Producing Hepatitis C Virus Particle
    Publication number: 20080220019
    Abstract: The present invention provides a method for replicating efficiently an RNA containing fulllength HCV genomic sequence and a method for producing HCV virus particles containing fulllength HCV replicon RNA or fulllength HCV genomic RNA by using a cell culture system. Further, the present invention relates to a method for producing hepatitis C virus particles which comprises culturing a cell, into which a replicon RNA comprising a nucleotide sequence comprising a fulllength genomic RNA sequence of hepatitis C virus of the genotype 2a, at least one selectable marker gene and/or at least one reporter gene and at least one IRES sequence or the fulllength genomic RNA of hepatitis C virus of the genotype 2a is introduced, and generating virus particles in the culture medium. Still further the present invention relates also to a hepatitis C vaccine and an antibody against hepatitis C virus particles.
    Type: Application
    Filed: February 21, 2005
    Publication date: September 11, 2008
    Applicants: Tokyo Metropolitan Organization for Medical Research, Toray Industries, Inc.
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Jun-ichi Tanabe, Saburo Sone
  • Nucleic Acid Construct Containing a Nucleic Acid Derived From the Genome of Hepatitis C Virus (Hcv) of Genotype 2A, and a Cell Having Such Nucleic Acid Construct Introduced Therein
    Publication number: 20080032323
    Abstract: The present invention relates to a replicon RNA comprising a nucleotide sequence at least containing the 5? untranslated region, the nucleotide sequence encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein, and the 3? untranslated region on the genomic RNA of hepatitis C virus of genotype 2a.
    Type: Application
    Filed: November 25, 2003
    Publication date: February 7, 2008
    Applicants: TORAY INDUSTRIES, INC, TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date